|Bid||209.30 x 800|
|Ask||0.00 x 1200|
|Day's Range||227.06 - 231.63|
|52 Week Range||191.53 - 248.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 1, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||3.00 (1.29%)|
|1y Target Est||252.65|
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Becton Dickinson and Company (NYSE:BDX) a safer option. Risk-averse investors who are attracted to diversifiedRead More...
NEW YORK, June 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Matthews ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Medical Instruments & Supplies equities: Akers Biosciences Inc. (NASDAQ: AKER), Antares Pharma Inc. (NASDAQ: ATRS), Baxter International Inc. (NYSE: BAX), and Becton, Dickinson and Co. (NYSE: BDX).
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want access to our free earnings report on Becton, Dickinson and Co. (NYSE: BDX) ("BD"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BDX. The Company reported its financial results on May 03, 2018, for the second quarter of the fiscal year 2018 (Q2 FY18). The global medical technology Company surpassed market estimates for revenues and earnings for Q2 FY18.
In the news release, BD to Present at Investor Healthcare Conferences, issued June 1, 2018 by BD (Becton, Dickinson and Company) over PR Newswire, we are advised by the company that the Goldman Sachs 38th ...
Stock investors looking for long-term growth plays in the health care space may seek guidance from Fidelity Fund manager Eddie Yoon, who oversees more than $35 billion in assets and leads the firm's health sector with a team of 12 investment professionals.
BD Pyxis™ ES Refrigerator Expands Enterprise-wide Medication Management Solutions from BD to Improve Refrigerated Medication Management and Security First Demonstration Unveiled During 2018 American Society ...
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FRANKLIN LAKES, N.J. , June 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming ...
Eddie Yoon spent his college years studying premed and playing golf at Brown University. Joining the firm as an analyst in 2006, he rose quickly, becoming portfolio manager of Fidelity Select Medical Technology and Devices Portfolio (FSMEX) in 2007 and Fidelity Select Health Care Portfolio (FSPHX) in 2008.
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom Polen, president of BD, and will be responsible for leading all research and development (R&D) activities for the company, including developing the current and future product portfolio. Since the completion of the C. R. Bard, Inc. transaction, DeFord has served as senior vice president of R&D for the Interventional Segment at BD.
Medical devices is another industry that Jim Cramer believes will hold up better in this current environment of volatile energy prices and interest rates. Let's take a look at five companies in this space, Baxter International Inc. The chart and indicators of Baxter International show underlying strength and could outperform the averages in the days and weeks ahead.
Today we’re going to take a look at the well-established Becton Dickinson and Company (NYSE:BDX). The company’s stock received a lot of attention from a substantial price movement on theRead More...
While small-cap stocks, such as Budimex SA (WSE:BDX) with its market cap of ZŁ4.67B, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
SHANGHAI/CHICAGO, May 11 (Reuters) - Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free earnings report on Illumina, Inc. (NASDAQ: ILMN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ILMN. Illumina reported its first quarter fiscal 2018 operating and financial results on April 24, 2018. The genetic testing tools Company outperformed top- and bottom-line expectations.
Today, Becton, Dickinson and Company (BDX), or BD, released its 1Q18 earnings results for the quarter that ended on March 31. The company reported strong sales and earnings results, surpassing Wall Street estimates. Also, BD raised its fiscal 2018 outlook during its 2Q18 earnings release.